Mallinckrodt PLC

Sanofi-aventis is a division of its namesake European parent company, which is one of the world s largest pharmaceutical companies. Backed by a world-class research and development organization, the company develops leading positions in nearly 10 major therapeutic areas that include cardiovascular disease, thrombosis, oncology, diabetes, central nervous system, internal medicine and vaccines. The Sanofi-aventis group employs approximately 14,000 employees in the United States located at nearly 15 geographical sites throughout the country. Of these, approximately 8,000 are field sales and medical affairs representatives, making the company s sales force one of the largest in the U.S. pharmaceutical industry. Some of its products include Actonel, Allegra, Ambien, Eloxatin, Nasacort, Plavix, Taxotere and Uroxatral. Sanofi-aventis maintains a location in Bridgewater, N.J.

Merck & Company, Inc. is one of the leading research-driven pharmaceutical companies in the world. The company works to discover, develop, manufacture and market vaccines and medicines to address unmet medical needs. Merck & Company devotes efforts to increase access to necessary medicines. The company offers a variety of far-reaching programs that donate Merck medicines and help deliver them. Merck & Company also publishes unbiased health information as a not-for-profit service. The company has locations in Argentina, Venzuela, Ecuador, Canada, Puerto Rico, Mexico, Columbia, Peru, Chile, the Dominican Republic and the United States. Richard T. Clark has been the chief executive officer of Merck & Company for more than a year. He has been with the biotech and pharmaceutical firm of rover 34 years. Clark earned a BA degree from Washington & Jefferson College, and a MBA from the American University. Merck & Company, Inc. was established in 1891 and maintains its headquarters in Whitehouse Station, N.J.

Kyowa Kirin Inc., located in Bedminster, NJ, is a global biopharmaceutical company dedicated to accelerating the discovery and development of innovative medicines that address unmet medical needs. With over 30 years of experience, the company has built a portfolio of specialty medicines and is committed to advancing breakthroughs in therapeutic areas such as nephrology, oncology, immunology, and neurology. Grounded in expertise in antibody engineering, Kyowa Kirin fosters a culture of collaboration and aims to ensure that patients can access the treatments and support they need. The organization's focus on novel scientific research and development continues to drive its mission to create first-in-class therapies that can transform medicine and improve lives. Generated from the website